Crohn's disease trials in Spain

In Spain 37 Also abroad 422

37 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
Where
Badalona, Barcelona, Ferrol, Madrid, Pontevedra, Santa Cruz de Tenerife, Torrejón de Ardoz, Valencia, Zaragoza
Age
18 years and over
People
567 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to join2024-518296-56-00 · EU 2024-518296-56-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Where
Badalona, Barcelona, Ferrol, Madrid, Pontevedra, Santa Cruz de Tenerife, Torrejón de Ardoz, Valencia, Zaragoza
Age
16 years to 80 years
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06430801 · EU 2023-508636-61-00
Phase 2Taking people
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Where
Ferrol, Lleida, Madrid, Majadahonda, Sevilla, Valencia
Age
18 years to 85 years
People
385 worldwide
Run by
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
See details and how to joinNCT06226883 · EU 2023-508158-24-00
Phase 3Taking people
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Where
Barcelona, Ferrol, Gijón, Madrid, Oviedo, Pamplona, Seville, Valencia
Age
18 years to 70 years
People
290 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06937099 · EU 2024-520210-21-00
Phase 3Taking people
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Where
Córdoba, Sabadell, Valencia
Age
2 years to 17 years
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05923073 · EU 2023-504735-41-00
Phase 3Taking people
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Where
Santiago de Compostela, Valencia
Age
3 years to 64 years
People
196 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00
Phase 2/3Taking people
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Where
Barcelona, Gijón, Girona, Madrid, Santiago de Compostela, Sevilla, Valencia
Age
18 years and over
People
1,092 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07196722 · EU 2025-521382-27-00
Phase 3Taking people
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Where
Alicante, Barcelona, Ferrol, Gijón, Girona, Madrid, Navarra, Santiago de Compostela, Seville
Age
18 years and over
People
530 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07499232
Phase 3Taking people
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Where
Ferrol, Gijón, Madrid, Sevilla, Valencia, Vigo
Age
18 years and over
People
460 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07577843 · EU 2026-525922-39-00
No phaseNot yet taking people in Spain
A Real-World Study of Guselkumab Persistence and Effectiveness in Participants With Crohn's Disease or Ulcerative Colitis
Where
Santiago de Compostela
Age
18 years and over
People
200
Run by
Janssen-Cilag, S.A.
See details and how to joinNCT07848737
Phase 2Taking people
A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
Where
Barcelona, Madrid, Sevilla
Age
18 years to 75 years
People
99 worldwide
Run by
Sanofi
See details and how to joinNCT06958536 · EU 2024-517016-30-00
Phase 4Taking people
A study to measure mirikizumab levels in breast milk of lactating participants receiving mirikizumab therapeutically for an approved indication
Where
Madrid
People
16 worldwide
Run by
Eli Lilly & Co.
See details and how to join2025-522362-78-00 · EU 2025-522362-78-00
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Alcorcón, Fuenlabrada, Madrid, Majadahonda, Zaragoza
Age
16 years to 80 years
People
425 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819891 · EU 2024-513054-30-00
Phase 3Taking people
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
Gijón, Huelva, Madrid, Ourense
Age
16 years to 80 years
People
980 worldwide
Run by
Sanofi
See details and how to joinNCT07184931
Phase 3Taking people
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Where
Esplugues De Llobregat, Ferrol, Madrid, Málaga
Age
2 years to 17 years
People
110 worldwide
Run by
AbbVie
See details and how to joinNCT05995353 · EU 2022-502050-14-00
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Córdoba, Galdakao, Madrid, Santa Cruz de Tenerife, Santander, Valencia, Valladolid
Age
16 years to 80 years
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819878 · EU 2024-513053-69-00
Phase 2Taking people
A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease
Where
Barcelona, Oviedo, Pamplona, Sabadell, Santander
Age
18 years and over
People
160 worldwide
Run by
Agomab Spain S.L.U.
See details and how to join2026-525197-19-00 · EU 2026-525197-19-00
Phase 3Taking people
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Where
Ferrol, Madrid, Sevilla, Valencia
Age
2 years to 17 years
People
70 worldwide
Run by
Takeda
See details and how to joinNCT06405087 · EU 2023-508804-39-00
Phase 3Taking people
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Where
Córdoba, Esplugues de Llobregat, Sabadell, Valencia
Age
2 years to 19 years
People
150 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT04844606
Phase 3Taking people
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Where
Córdoba, Sabadell, Valencia
Age
2 years to 17 years
People
90 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05509777 · EU 2024-511472-32-00
No phaseNot yet taking people in Spain
Artificial Intelligence For Outcomes Research in Crohn's Disease: Digital Pathology Assessment of Fibrosis and Association With Patient History and Clinical Outcomes
Where
Seville
Age
18 years to 80 years
People
100
Run by
PharmaNest, Inc
See details and how to joinNCT07795476
Phase 2Taking people
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Where
Fuenlabrada, Madrid, Santiago de Compostela, Sevilla, Valencia, Vigo
Age
18 years to 75 years
People
590 worldwide
Run by
AbbVie
See details and how to joinNCT06548542 · EU 2024-513009-30-00
Phase 3Taking people
Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year
Where
Alicante, Barcelona, Ferrol, Gijón, Girona, Pamplona, Santiago de Compostela, Sevilla, Torrejón de Ardoz
Age
18 years and over
People
302 worldwide
Run by
Janssen Cilag International
See details and how to join2025-521590-13-00 · EU 2025-521590-13-00
Phase 3Taking people
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
Where
Ferrol, Madrid, Sevilla, Valencia
Age
2 years to 17 years
People
70 worldwide
Run by
Takeda
See details and how to joinNCT06100289 · EU 2023-503188-40-00
No phaseTaking people
Prospective Risk Evaluation and Detection of Crohn's Disease in First-degree Relatives
Where
Galdakao
Age
16 years to 35 years
People
10,000 worldwide
Run by
GLSMED Learning Health S.A.
See details and how to joinNCT07316621